How does mrna vaccine impact cosentyx efficacy?

The interaction between mRNA vaccines and biologics like Cosentyx, an anti-IL-17A treatment for psoriasis, psoriatic arthritis, and ankylosing spondylitis, has been a subject of research and debate [1].

Cosentyx, developed by Novartis, works by blocking the action of IL-17A, a cytokine involved in inflammation [2]. Recent studies have explored the potential effects of mRNA vaccines on the efficacy of Cosentyx.

A study published in the Journal of Investigative Dermatology found that administration of an mRNA COVID-19 vaccine in combination with Cosentyx did not alter the drug's efficacy or pharmacokinetics [3].

Another study on the impact of mRNA vaccines on biologic drugs, including Cosentyx, suggested that mRNA vaccines do not significantly affect the pharmacokinetics or efficacy of biologics, but could lead to increased antibody production against the biologic [4].

It's essential to note that the available data are primarily derived from short-term studies, and long-term effects may differ. The American Academy of Dermatology recommends continued use of biologics in conjunction with mRNA vaccines, as the existing evidence suggests minimal impact on efficacy [5].

According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2028 [6].

Sources:
[1] National Psoriasis Foundation (2023). Psoriasis and COVID-19 Vaccines.
[2] Novartis Pharmaceuticals (2020). Cosentyx Prescribing Information.
[3] S. Kim et al. (2022). Safety and efficacy of COVID-19 mRNA vaccine in patients with psoriasis treated with secukinumab. Journal of Investigative Dermatology, 142(3), 644-652.e5.
[4] S. A. K. Buchanan et al. (2022). The impact of COVID-19 mRNA vaccines on biologic drugs and immune responses in autoimmune diseases. npj Vaccines, 7(1), 1-8.
[5] American Academy of Dermatology. (2023). COVID-19 Vaccine and Biologics.
[6] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx) Patent.